PT2948143T - Uso de compostos de fenoxipropilamina para tratar a depressão - Google Patents

Uso de compostos de fenoxipropilamina para tratar a depressão

Info

Publication number
PT2948143T
PT2948143T PT147431589T PT14743158T PT2948143T PT 2948143 T PT2948143 T PT 2948143T PT 147431589 T PT147431589 T PT 147431589T PT 14743158 T PT14743158 T PT 14743158T PT 2948143 T PT2948143 T PT 2948143T
Authority
PT
Portugal
Prior art keywords
treat depression
phenoxypropylamine compounds
phenoxypropylamine
compounds
depression
Prior art date
Application number
PT147431589T
Other languages
English (en)
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of PT2948143T publication Critical patent/PT2948143T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT147431589T 2013-01-24 2014-01-24 Uso de compostos de fenoxipropilamina para tratar a depressão PT2948143T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756208P 2013-01-24 2013-01-24
US201361799482P 2013-03-15 2013-03-15
US201361852149P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PT2948143T true PT2948143T (pt) 2021-06-03

Family

ID=51208168

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147431589T PT2948143T (pt) 2013-01-24 2014-01-24 Uso de compostos de fenoxipropilamina para tratar a depressão

Country Status (23)

Country Link
US (2) US20140206722A1 (pt)
EP (2) EP3925608A3 (pt)
JP (2) JP6422890B2 (pt)
KR (4) KR102587177B1 (pt)
CN (2) CN105377255A (pt)
AU (4) AU2014209200B2 (pt)
BR (1) BR112015017628A2 (pt)
CA (2) CA2898279C (pt)
CL (1) CL2015002069A1 (pt)
DK (1) DK2948143T3 (pt)
ES (1) ES2875058T3 (pt)
IL (4) IL287727B2 (pt)
MX (1) MX2015009445A (pt)
MY (1) MY185908A (pt)
NZ (2) NZ750189A (pt)
PE (1) PE20151888A1 (pt)
PH (1) PH12015501643B1 (pt)
PL (1) PL2948143T3 (pt)
PT (1) PT2948143T (pt)
RU (2) RU2725112C2 (pt)
SG (2) SG11201505737YA (pt)
WO (1) WO2014117003A1 (pt)
ZA (2) ZA201505114B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190013847A (ko) * 2016-05-25 2019-02-11 미쓰비시 타나베 파마 코퍼레이션 불안 장애를 치료하기 위한 (2S)-1-[4-(3,4-디클로로페닐)피페리딘-1-일]-3-[2-(5-메틸-1,3,4-옥사디아졸-2-일)벤조[b]푸란-4-일옥시]프로판-2-올 또는 그의 대사산물
US11541201B2 (en) * 2017-10-04 2023-01-03 Neurogeneces, Inc. Sleep performance system and method of use
US11766430B2 (en) 2018-09-04 2023-09-26 Minerva Neurosciences, Inc. Methods of using a phenoxypropylamine compound to treat pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
KR100882544B1 (ko) * 1999-05-24 2009-02-12 미쓰비시 타나베 파마 코퍼레이션 페녹시프로필아민 화합물
US6784180B2 (en) * 1999-12-20 2004-08-31 Eli Lilly And Company Piperidines derivatives and their use as serotonin receptor antagonists
RU2424799C1 (ru) * 2010-03-29 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Способ коррекции депрессивных расстройств производными тиетан-1,1-диоксида в эксперименте

Also Published As

Publication number Publication date
SG11201505737YA (en) 2015-08-28
NZ750189A (en) 2020-08-28
EP2948143B1 (en) 2021-05-05
MY185908A (en) 2021-06-14
KR102587177B1 (ko) 2023-10-06
WO2014117003A1 (en) 2014-07-31
RU2725112C2 (ru) 2020-06-29
MX2015009445A (es) 2016-01-14
EP2948143A4 (en) 2017-02-22
ES2875058T3 (es) 2021-11-08
PH12015501643A1 (en) 2015-10-12
JP6422890B2 (ja) 2018-11-14
RU2020120236A (ru) 2020-09-01
AU2019200512B2 (en) 2020-04-16
IL287727A (en) 2021-12-01
EP2948143A1 (en) 2015-12-02
IL287727B2 (en) 2024-08-01
KR102247960B1 (ko) 2021-05-07
IL239928B (en) 2021-04-29
AU2014209200A1 (en) 2015-07-30
BR112015017628A2 (pt) 2017-07-11
JP2018172400A (ja) 2018-11-08
NZ709967A (en) 2020-05-29
IL278109A (en) 2020-11-30
CA2898279C (en) 2022-05-17
IL278109B (en) 2022-03-01
IL239928A0 (en) 2015-08-31
AU2020205268A1 (en) 2020-08-06
ZA201505114B (en) 2023-09-27
RU2015135358A (ru) 2017-03-03
CN110664813A (zh) 2020-01-10
EP3925608A2 (en) 2021-12-22
JP2016510331A (ja) 2016-04-07
PE20151888A1 (es) 2016-01-13
KR20220112865A (ko) 2022-08-11
PL2948143T3 (pl) 2021-12-13
CA2898279A1 (en) 2014-07-31
PH12015501643B1 (en) 2015-10-12
IL287727B1 (en) 2024-04-01
IL311363A (en) 2024-05-01
KR20210047368A (ko) 2021-04-29
JP6657315B2 (ja) 2020-03-04
CL2015002069A1 (es) 2016-05-20
CN105377255A (zh) 2016-03-02
ZA202207530B (en) 2023-10-25
AU2022241458A1 (en) 2022-10-20
US20140206722A1 (en) 2014-07-24
AU2014209200B2 (en) 2018-11-01
AU2020205268B2 (en) 2022-07-07
SG10201706035QA (en) 2017-08-30
KR102172351B1 (ko) 2020-11-02
DK2948143T3 (da) 2021-07-26
CA3150231A1 (en) 2014-07-31
US20200223838A1 (en) 2020-07-16
KR20150120987A (ko) 2015-10-28
AU2019200512A1 (en) 2019-02-14
KR20200086377A (ko) 2020-07-16
EP3925608A3 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1219236A1 (zh) 猝倒的治療
HK1213818A1 (zh) 依帕列淨的治療用途
RS63939B1 (sr) Inhibitori lizin specifične demetilaze-1
SI2981271T1 (sl) Terapevtske uporabe empagliflozina
EP2958964A4 (en) TREATMENT OF FREQUENTLY AFFECTED SURFACES TO IMPROVE HYGIENE
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
ZA201602831B (en) Use of lactones
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
EP2986294A4 (en) COMPOUNDS FOR THE TREATMENT OF PAIN
EP2986295A4 (en) COMPOUNDS FOR THE TREATMENT OF PAIN
GB2525530B (en) Treatment of hard surfaces
HK1198422A1 (en) Novel uses of colossolactones
GB201314303D0 (en) Treatment of HPV